Literature DB >> 25785110

Associations between human aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension.

Xu Ji1, Hua Qi1, Dong-Bao Li1, Rong-Kun Liu1, Yang Zheng1, Hai-Ling Chen1, Jin-Cheng Guo1.   

Abstract

Aldosterone synthase is a mitochondrial enzyme that catalyzes the conversion of 11-deoxycorticosterone to the potent mineralocorticoid aldosterone. The gene encoding aldosterone synthase, CYP11B2, is associated with essential hypertension. But if the genetic variations in aldosterone synthesis could influence the antihypertensive response to Valsartan is not clear. A Chinese sample of 502 persons (217 women) was studied, which was divided into the hypertensive group (EH) of 345 persons and the normotensive group (NB) of 157 persons. Subjects were genotyped through the use of the polymerase chain reaction for the diallelic polymorphisms in CYP11B2. 98 persons of the essential hypertension group received 4 weeks therapy with valsartan. Blood pressure, 24-hour ambulatory blood pressure, biochemical index were also determined. The frequency of CC+CT genotypes in hypertensive group was significantly higher than that in normotensive group (P<0.05), the frequency of C allele of gene CYP11B2 (-344T/C) in hypertensive group was significantly higher than that in normotensive group (P<0.01). The descending values of SBP (systolic blood pressure), DBP (diastolic blood pressure), MAP (mean arterial pressure), 24 h SBP (mean SBP of 24 hours), 24 h DBP (mean DBP of 24 hours), 24 h MAP (mean arterial pressure of 24 hours) of CC+CT genotype group were significantly higher than those of the TT genotype group (P<0.05). The aldosterone synthase CYP11B2 (-344T/C) gene polymorphism is associated with essential hypertension in Chinese. And the aldosterone synthase CYP11B2 (-344T/C) gene polymorphism may be the predictor of the antihypertensive response to Valsartan.

Entities:  

Keywords:  CYP11B2; Genetics; aldosterone; antihypertensive response; blood pressure monitoring; hypertension

Year:  2015        PMID: 25785110      PMCID: PMC4358565     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

Review 1.  Mechanisms of hypertension: the expanding role of aldosterone.

Authors:  E Marie Freel; John M C Connell
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

2.  [Effect of CYP11B2 gene -344T/C polymorphism on renin-angiotensin-aldosterone system activity and blood pressure response to hydrochlorothiazide].

Authors:  Yun Li; Peng Yang; Shou-ling Wu; Ju-xiang Yuan; Ying Wu; Dan-dan Zhao; Sheng Xu; Li-ping Zhao; Man-jiang Sun; Li-ming Chu; Da-shuang Lu
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2012-02

3.  Genetic polymorphism of CYP11B2 gene and hypertension in Japanese.

Authors:  S Tamaki; N Iwai; Y Tsujita; M Kinoshita
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients.

Authors:  Yun Li; Yong Zhou; Peng Yang; Jian Qing Niu; Ying Wu; Dan Dan Zhao; Shou Ling Wu
Journal:  Clin Exp Hypertens       Date:  2011-01-26       Impact factor: 1.749

6.  Association of the C-344T polymorphism of CYP11B2 gene with essential hypertension in Hani and Yi minorities of China.

Authors:  Wenru Tang; Hongyan Wu; Xuhong Zhou; Baowen Cheng; Yongli Dong; Li He; Haijing Yu; Lin Xu; Jing Lu; Kaiyuan Li; Chunjie Xiao
Journal:  Clin Chim Acta       Date:  2005-08-26       Impact factor: 3.786

Review 7.  Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function.

Authors:  P C White; A Hautanen; M Kupari
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

8.  Association of the -344T/C aldosterone synthase gene variant with essential hypertension.

Authors:  Z Hlubocká; M Jáchymová; S Heller; V Umnerová; V Danzig; V Lánská; K Horký; A Linhart
Journal:  Physiol Res       Date:  2008-12-17       Impact factor: 1.881

9.  Genetic determination of plasma aldosterone levels in essential hypertension.

Authors:  L Pojoga; S Gautier; H Blanc; T T Guyene; O Poirier; F Cambien; A Benetos
Journal:  Am J Hypertens       Date:  1998-07       Impact factor: 2.689

10.  Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.

Authors:  Børge G Nordestgaard; Kimmo Kontula; Marianne Benn; Björn Dahlöf; Ulf de Faire; Jonathan M Edelman; Erik Eliasson; Frej Fyhrquist; Darcy A Hille; Hans Ibsen; Paulette A Lyle; Kåre Berg; Mia Sandberg; Amar A Sethi; Peggy H Wong; Ingrid Os
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

View more
  4 in total

1.  Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Authors:  Mariana Babayeva; Brigitte Azzi; Zvi G Loewy
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Pharmacogenomics of Hypertension Treatment.

Authors:  Jacek Rysz; Beata Franczyk; Magdalena Rysz-Górzyńska; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2020-07-01       Impact factor: 5.923

3.  Effect of ACE, ACE2 and CYP11B2 gene polymorphisms and noise on essential hypertension among steelworkers in China: a case-control study.

Authors:  Xiaohong Zhang; Ying Wang; Yao Zheng; Juxiang Yuan; Junwang Tong; Jingya Xu; Qinglin Li; Peishuai Li; Shoufang Jiang; Zhaoyang Wang; Feng Chai; Xiangwen Li
Journal:  BMC Med Genomics       Date:  2022-02-08       Impact factor: 3.063

Review 4.  Essential hypertension in children, a growing worldwide problem.

Authors:  Mohammadreza Sabri; Alaleh Gheissari; Marjan Mansourian; Noushin Mohammadifard; Nizal Sarrafzadegan
Journal:  J Res Med Sci       Date:  2019-12-23       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.